

Trends and Practices in Early versus Late Initiation of Renal Replacement Therapy in South Korea and Taiwan

*Soie Kwon^{1, 2}, Ping-Hsun Wu³, Yaerim Kim, Jeonghwan Lee,
Dong Ki Kim, Yon Su Kim, Chun Soo Lim, Ming-Yen Lin, Yi-Wen Chiu³,
Shang-Jyh Hwang³, Jung Pyo Lee*



When to start RRT (Renal replacement therapy)

<KDIGO 2024 Guideline>

5.4 Timing the initiation of dialysis

Practice Point 5.4.1: Initiate dialysis based on a composite assessment of a person's symptoms, signs, QoL, preferences, level of GFR, and laboratory abnormalities.

Practice Point 5.4.2: Initiate dialysis if the presence of **one or more of the following situations is evident** (Table 41). This often but not invariably occurs in the GFR range **between 5 and 10 ml/min per 1.73 m²**.

Practice Point 5.4.3: Consider planning for preemptive kidney transplantation and/or dialysis access in adults when the GFR is <15–20 ml/min per 1.73 m² or risk of KRT is >40% over 2 years.





Table 41 | Indications for the initiation of dialysis

Symptoms or signs attributable to kidney failure (e.g., neurological signs and symptoms attributable to uremia, pericarditis, anorexia, medically resistant acid-based or electrolyte abnormalities, intractable pruritus, serositis, and acid-base or electrolyte abnormalities)


Inability to control volume status or blood pressure

Progressive deterioration in nutritional status refractory to dietary intervention, or cognitive impairment

Different regulations RRT initiation



Each nephrologist is independently allowed to initiate RRT at their clinical discretion, when eGFR falls <15 mL/min/1.73 m²



National insurance system generally restricts initiation to cases, where eGFR falls < 10 mL/min/1.73 m²

Goal

- 1) Compares RRT initiation practices of South Korea and Taiwan, focusing on changes in the eGFR**
- 2) Whether the difference in RRT initiation timing is associated with the mortality difference**

Cohort Population

- **South Korea**


- Two tertiary referral centers (SNUH, BRMH)
- 2001~2021

 서울대학교병원

 서울대학교병원운영
서울특별시보라매병원

- **Taiwan**

- One tertiary referral center (Taiwan Kidney Outcome (TAKO) cohort from Kaohsiung Medical University Hospital [KNUH] care system
- 2005 ~2021





► Comparison of baseline characteristics of two countries



| | South Korea 5,967 | Taiwan 2,277 | Total 8,244 | |
|---------------------------------|----------------------|---------------------|---------------------|--------|
| Patients (N) | | | | |
| Age (year) | 60.0 [48.0;70.0] | 65.0 [56.0;74.0] | 61.0 [50.0;71.0] | <0.001 |
| Body mass index | 22.6 [20.4;25.1] | 24.3 [21.7;27.2] | 23.0 [20.7;25.7] | <0.001 |
| Sex (male, %) | 3508 (58.8%) | 1239 (54.4%) | 4747 (57.6%) | <0.001 |
| Comorbidities (N, %) | | | | |
| Diabetes mellitus | 2781 (46.6%) | 1546 (67.9%) | 4327 (52.5%) | <0.001 |
| Hypertension | 3674 (61.6%) | 2178 (95.7%) | 5852 (71.0%) | <0.001 |
| Dyslipidemia | 887 (14.9%) | 1097 (48.2%) | 1984 (24.1%) | <0.001 |
| Coronary artery disease | 463 (7.8%) | 412 (18.1%) | 875 (10.6%) | <0.001 |
| Heart failure | 398 (6.7%) | 634 (27.8%) | 1032 (12.5%) | <0.001 |
| Laboratory findings | | | | |
| Blood urea nitrogen, mg/dL | 68.0 [51.0;90.0] | 102.3 [77.4;130.2] | 75.0 [55.0;103.0] | <0.001 |
| eGFR, ml/min/1.73m ² | 7.1 [5.2; 9.7] | 3.9 [3.1; 5.0] | 6.0 [4.2; 8.7] | <0.001 |
| Albumin, g/L | 3.6 [3.2; 4.0] | 3.6 [3.2; 4.0] | 3.6 [3.2; 4.0] | 0.467 |
| Hemoglobin, g/dL | 9.7 [8.6;10.8] | 9.0 [8.1;10.0] | 9.5 [8.5;10.6] | <0.001 |
| Potassium, mmol/L | 4.8 [4.2; 5.4] | 4.2 [3.8; 4.8] | 4.6 [4.1; 5.2] | <0.001 |
| Total CO ₂ , mmol/L | 20.0 [17.0;23.1] | 19.4 [16.0;23.1] | 20.0 [16.6;23.1] | <0.001 |
| Glucose, mg/dL | 107.0 [91.0;140.5] | 104.0 [93.0;127.0] | 106.0 [92.0;137.0] | 0.002 |
| Hemoglobin A1c, % | 6.3 [5.7; 7.2] | 6.0 [5.4; 6.8] | 6.2 [5.6; 7.1] | <0.001 |
| Phosphate, mg/dL | 4.9 [4.1; 5.9] | 5.7 [4.7; 7.0] | 5.1 [4.2; 6.2] | <0.001 |
| Total cholesterol, mg/dL | 150.0 [125.0;180.0] | 161.0 [133.0;193.0] | 152.0 [126.9;183.0] | <0.001 |
| UPCR, g/g | 3.3 [1.7; 6.4] | 3.6 [1.7; 6.7] | 3.4 [1.7; 6.4] | 0.129 |
| Intact PTH | 120.0 [52.0;246.0] | 272.2 [150.4;443.4] | 200.8 [98.3;378.0] | <0.001 |

| | South Korea 5,967 | Taiwan 2,277 | Total 8,244 | |
|-------------------------------|----------------------|-----------------|----------------|--------|
| Patients (N) | | | | |
| Medication usage | | | | |
| Anti-diabetic medications | 1310 (22.0%) | 1412 (62.0%) | 2722 (33.0%) | <0.001 |
| Metformin | 95 (1.6%) | 41 (1.8%) | 136 (1.6%) | 0.57 |
| Sulfonylurea | 573 (9.6%) | 809 (35.5%) | 1382 (16.8%) | <0.001 |
| DPP4-inhibitor | 487 (8.2%) | 745 (32.7%) | 1232 (14.9%) | <0.001 |
| TZD | 98 (1.6%) | 96 (4.2%) | 194 (2.4%) | <0.001 |
| Insulin | 568 (9.5%) | 1077 (47.3%) | 1645 (20.0%) | <0.001 |
| Anti-hypertensive medications | 3473 (58.2%) | 2154 (94.6%) | 5627 (68.3%) | <0.001 |
| RAS Blocker | 2702 (45.3%) | 1426 (62.6%) | 4128 (50.1%) | <0.001 |
| Diuretics | 1664 (27.9%) | 1796 (78.9%) | 3460 (42.0%) | <0.001 |
| Statin | 1983 (33.2%) | 1137 (49.9%) | 3120 (37.8%) | <0.001 |



► Differences in eGFR Trends Between South Korea and Taiwan



► Subgroup analysis (1) Age



► Subgroup analysis (2) Other comorbidities





► 5 Year Mortality – Kaplan Meier



1457/5967 = 24.4%



658/2777 = 28.9%



► 5 Year Mortality – Cox analysis


| | | eGFR 10 ≤ <15 | | | eGFR 5 ≤ <10 | | | eGFR <5 | | |
|--------|------------|--|---------------|---------|--------------|--------|---------|---------|---------------|---------|
| | | HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value |
| Korea | Univariate | 1.024 | 0.9037-1.1602 | 0.71 | 1 | Ref | | 0.765 | 0.6673-0.8757 | <0.001 |
| | Model 1 | 0.978 | 0.8629-1.1092 | 0.7325 | | | | 0.927 | 0.8082-1.0641 | 0.2827 |
| | Model 2 | 1.018 | 0.8943-1.582 | 0.7894 | | | | 0.904 | 0.7828-1.0443 | 0.1704 |
| | Model 3 | 1.014 | 0.8912-1.1542 | 0.8306 | | | | 0.921 | 0.7968-1.0639 | 0.2626 |
| Taiwan | Univariate | Data were excluded due to lack of representativeness | | | 1 | Ref | | 0.440 | 0.3749-0.5157 | <0.001 |
| | Model 1 | | | | | | | 0.555 | 0.4702-0.6541 | <0.001 |
| | Model 2 | | | | | | | 0.528 | 0.4253-0.6555 | <0.001 |
| | Model 3 | | | | | | | 0.533 | 0.4293-0.6626 | <0.001 |

Model 1 : Gender, Age, Hospital, Year, DM, HTN, DL



Model 2 : Model 1 + Laboratory (BUN, Albumin, Hb, Phosphate, Total cholesterol)

Model 3 : Model 2 + + Medication (DM med, HTN med, Diuretics, Statin)

Reference: Korea, eGFR 5 ≤ <10, Cox Model 3



► 5 Year Mortality – Propensity score matching with Cox



► Conclusion

- RRT was initiated earlier in Korea compared to Taiwan
 - Taiwan has maintained a stable eGFR threshold for dialysis initiation due to government regulations, whereas Korea has shown a trend toward earlier initiation in recent years
 - Even after adjustment using Cox regression and PSM, Korean patients with eGFR 5–10 at dialysis initiation show better survival.
- This suggests that, for patients with eGFR 10–15, earlier dialysis initiation based on clinical judgment may potentially improve survival.

► Limitations

- This retrospective observational study has limitations
 - Three-center design limits generalizability to national level
 - Lack of data on uremic symptoms (a key factor for dialysis initiation)
 - Inability to assess differences by RRT modality comparison
 - Unable to confirm whether pre-RRT preparation for modality was performed
 - Possible residual bias beyond RRT start timing that may explain higher survival in Korean patients



Thank you for your attention



중앙대학교병원
CHUNG-ANG UNIVERSITY HOSPITAL